Commercially supplied as a white to off-white free-flowing powder, silicified microcrystalline cellulose veterinary grade is a co-processed cellulosic excipient rather than a pharmacologically active substance, although the designation API appears in some veterinary drug master files and commercial product names. The material consists of microcrystalline cellulose with a nominal **2.0 % w/w** colloidal silicon dioxide physically associated with the cellulose surface by a coprocessing step. When no veterinary-specific monograph exists, the product is controlled against the **USP-NF** monograph for silicified microcrystalline cellulose and, where required, the applicable microcrystalline cellulose monograph. The dosage-form list of tablets, injections, capsules, powders, granules, premix, and solutions defines processing targets rather than true solubility behavior: the powder is practically insoluble in water and organic solvents.

Trade designations follow particle-size and density classes. SMCC 50, SMCC 90, SMCC HD 90, and SMCC 90 LM are common in vendor technical literature. The **50 µm** grade is typically used in wet granulation and low-dose dry blends requiring rapid hydration and high surface coverage. The **90 µm** grade is intended for direct-compression tablet and capsule filling. High-density variants designated as HD grades and low-moisture variants designated as LM grades are available from multiple suppliers, but exact grade nomenclature is manufacturer-specific. The particle size distribution is normally verified by laser diffraction according to **USP <429>**, with d50 control bands such as **45–65 µm** and **80–110 µm** for the nominal 50 and 90 classes. Bulk density and tapped density are measured according to **USP <616>**, loss on drying according to **USP <731>**, and pH of an aqueous dispersion according to **USP <791>**. Table 1 gives typical release ranges reported in vendor technical bulletins.

In a direct-compression setting, the material is weighed and blended with the active pharmaceutical ingredient and a lubricant in a bin blender, V-blender, or low-shear drum blender. It is not a disintegrant, and high-compression formulations may require croscarmellose sodium at **1–3 % w/w** to maintain dissolution. The powder can be compressed on rotary tablet presses with standard concave or flat-faced tooling; typical compaction pressures for veterinary tablets are **100–180 MPa**, but the actual pressure must be established on a compaction simulator because powder compressibility depends on moisture, particle size, and lubricant mix. Magnesium stearate is typically added at **0.5–1.0 % w/w**; blending beyond **5 min** is generally unnecessary and may produce a lubricant film on the cellulosic surface.

The compaction behavior of silicified microcrystalline cellulose is predominantly plastic deformation with low elastic recovery. On a rotary tablet press with **10 mm** flat-faced tooling, compression forces of **10–20 kN** can produce tablets that pass **USP <1216>** friability testing, but capping may occur if precompression is inadequate or if the granule feed is over-lubricated. A precompression stage of **1–3 kN** is therefore common in direct-compression runs. The ejection force is typically lower than that of unmodified MCC at the same compaction pressure because of the coprocessed silicon dioxide, but the quantitative reduction varies with lubricant concentration, tooling condition, and turret speed. Published data for veterinary-grade silicified MCC in specific direct-compression matrices are limited; feasibility batches on an instrumented press are recommended.

For capsule filling, the material is processed on tamping-type or dosator-type machines. The **90 µm** grade is generally preferred for high-speed filling because of its higher bulk density and lower dustiness relative to the **50 µm** grade. In very small capsule sizes, bridging in powder feed tubes can still occur; adding an external glidant at **0.1–0.3 % w/w** may be necessary on vibratory feed systems. Capsule weight variation should be monitored from the first **100 capsules** after start-up because static charge on the cellulosic surface can elevate early fill variation. Static charge is minimized by maintaining ambient relative humidity at **40–55 % RH** and grounding metal contact surfaces. Tamping force values of **30–80 N** on dosator-type machines are reported for the **90 µm** grade, but these values are machine-specific and require confirmation.

What Distinguishes Silicified MCC From Unmodified MCC or a Simple Physical Blend?

Unmodified microcrystalline cellulose has high compactibility but poor flow, low bulk density, and high sensitivity to over-lubrication. Silicification deposits colloidal silicon dioxide on the cellulose surface, reducing interparticle friction and improving die fill. In a simple physical blend of microcrystalline cellulose and fumed silica, the silica can segregate during conveying; in the coprocessed product, the silica remains spatially associated with the cellulose, which is a critical advantage in low-dose veterinary premixes where segregation of glidant can shift content uniformity. The product is not a simple substitute for fumed silica. It provides less free-flowing improvement than a high-surface-area hydrophobic silica in some powder systems, but the flow benefit is distributed without an additional mixing step.

Compared with spray-dried lactose, the product is non-reducing and does not participate in Maillard browning with primary amine active ingredients. Compared with dicalcium phosphate dihydrate, it is less dense and less abrasive to tablet tooling; however, its lower bulk density can require larger die cavities for the same fill weight. Compared with crospovidone, it does not wick solvent rapidly and does not act as a superdisintegrant. It should not be used as the sole disintegrating agent in tablets that require rapid release. Published independent comparative data under veterinary-specific formulation conditions are limited; vendor technical bulletins provide most of the measurable differences.

Injection-Grade Suspension Behavior and Endotoxin Control

When the product is specified for injections, the intended use is as a suspending agent in aqueous veterinary suspensions or as a dry powder for reconstitution, not as a solute in a true solution. The powder is practically insoluble; therefore, finished products for subcutaneous or intramuscular use are suspensions or reconstitutable suspensions. Intravenous administration is not appropriate because of the particulate burden and the resulting risk of capillary occlusion. The injectable grade requires additional control of bacterial endotoxins according to **USP <85>**, sterility according to **USP <71>**, and particulate matter for the final injectable product according to **USP <788>**. Low-endotoxin grades are available, but published limit values for this specific veterinary grade are not uniform; the finished parenteral monograph must define the endotoxin limit based on dose and route.

Veterinary-grade material should not be confused with general tableting-grade material. Tableting grades may not carry endotoxin certificates; the injectable grade does. If the product is purchased as a veterinary grade for injections, the certificate of analysis should include endotoxin release data and sterility after the qualified sterilization step. Terminal sterilization of dry powder is typically performed by gamma irradiation; sterilization dose is established according to **ISO 11137**. Doses above **25 kGy** may cause chain scission in the cellulose matrix, discoloration, and reduced compactibility, but the exact threshold for a given batch depends on initial moisture and antioxidant load. Moist heat sterilization of the dry powder is generally not recommended because it can produce caking and browning. Sterile filtration is not possible because the material is insoluble and particulate. Where aseptic processing is required, the powder is handled in **ISO 14644** classified cleanrooms under low-humidity conditions.

When the Product Is Used in Premixes, Granules, and Feed Powders

In medicated feed premixes, the powder is used as a dry binder, anticaking agent, and carrier for oily or hygroscopic actives. It can be added directly to ribbon mixers, paddle mixers, or tumble mixers. Blend homogeneity is influenced by particle size; the **50 µm** grade typically provides faster dispersion in a low-dose premix, but it may generate more dust than the **90 µm** grade. Dust formation is controlled by the coprocessed silicon dioxide only to a limited extent; local exhaust ventilation is required in charging stations. The product absorbs atmospheric moisture above **60 % RH** and should be conditioned at **40–50 % RH** before blending if bulk bags have been stored in unheated warehouses. In a ribbon mixer, blend uniformity is assessed by sampling **10** locations and calculating coefficient of variation **≤ 5.0 %** for active loads above **0.1 % w/w**.

For wet granulation, the **90 µm** grade is typically used as a dry binder in high-shear granulators. Water or binder solution is added until a torque or power-draw endpoint is reached; fixed water percentages are unreliable because the pH, salt content, and hygroscopicity of the active ingredient can shift the wet mass consistency. Impeller speeds of **150–300 rpm** and chopper speeds of **1000–3000 rpm** are representative of pilot-scale high-shear equipment, but scale-up requires constant impeller tip speed and Froude number rather than fixed rpm. At levels below **10 % w/w** in a wet granulation, the material does not provide sufficient binding strength for brittle actives; a polymeric binder such as povidone or hydroxypropyl cellulose may be required. In fluid-bed granulation, the product may be less free-flowing than denser carriers but can be sprayed with binder solutions without excessive defluidization if the airflow rate is maintained above the minimum fluidization velocity.

For dried granules, the target particle-size distribution is typically **150–850 µm**, with fines below **150 µm** limited to **≤ 25 %** to prevent segregation and dust. Loss on drying after fluid-bed drying is typically controlled to **≤ 3.0 %**. These values are process targets rather than compendial limits. The finished medicated feed or premix is subject to **21 CFR 225** current good manufacturing practice for medicated feeds.

Where the dosage-form list includes solutions, the correct technical interpretation is a dry blend for reconstitution to a suspension or the use of the product as a suspending component in a multi-phasic liquid. The powder is practically insoluble in water, ethanol, propylene glycol, and glycerol. Aqueous dispersions at concentrations up to **20 % w/v** can be prepared with rotor-stator mixing at **500–1500 rpm** for **10–15 min**. Above **15 % w/v**, viscosity increases sharply and additional suspending agents such as xanthan gum or a carbomer may be needed. Sedimentation occurs on standing, and the label must require vigorous shaking before administration. In non-aqueous vehicles, settling rate changes with vehicle viscosity and interfacial properties; compatibility testing per the finished veterinary medicinal product protocol is required.

The product is incompatible with strong oxidizing agents, strong acids, and dry heat above **200 °C**; cellulosic dust clouds may be combustible. Strong alkaline treatment at elevated temperature can cause mercerization and partial dissolution. Pre-drying is required at process relative humidity above **60 %**. Storage in unlined fiber drums under high humidity may permit microbial growth and should be avoided for injectable-grade material. Residual solvent and elemental impurity controls are referenced to **VICH GL 18** and **USP <232>/<233>**; batch-specific certificates of analysis should be requested for each lot used in veterinary field trials or commercial manufacture.